Certified by Founder
Lodge
Rampart Bioscience
start up
United States
- Delhi, California
- 25/10/2023
- Series A
- $85,000,000
Rampart Bioscience is evolving a new class of medicines for patients with genetically driven diseases. We integrate capabilities from a variety of key scientific disciplines — including gene delivery, protein sciences and clinical translation — to leap beyond the limitations of current gene therapies.
Powered by our novel non-viral DNA delivery system, we are on a path to achieve higher standards for potency, durability, redosability and safety. Together, we are working to reshape the treatment landscape for people in dire need of better options.
- Industry Biotechnology Research
- Website https://rampartbio.com/
- LinkedIn https://www.linkedin.com/company/rampart-bioscience/about/
Brevo | $582,532,500 | (Dec 5, 2025)
Lumia Security | $18,000,000 | (Dec 5, 2025)
imper.ai | $28,000,000 | (Dec 5, 2025)
IMTC | $12,000,000 | (Dec 5, 2025)
Govstream.ai | $3,600,000 | (Dec 5, 2025)
SPhotonix Inc | $4,500,000 | (Dec 5, 2025)
Unlimited Industries | $12,000,000 | (Dec 5, 2025)
Paradigm Health | $78,000,000 | (Dec 5, 2025)
Guide Labs | $9,000,000 | (Dec 5, 2025)
7AI | $130,000,000 | (Dec 5, 2025)
Ply | $8,500,000 | (Dec 5, 2025)
Find Your Grind | $5,000,000 | (Dec 5, 2025)